Ipsen S.A. (IPSEF)
OTCMKTS
· Delayed Price · Currency is USD
125.37
0.00 (0.00%)
At close: Oct 22, 2024
Ipsen Revenue
Ipsen had revenue of 1.75B EUR in the half year ending June 30, 2024, with 16.95% growth. This brings the company's revenue in the last twelve months to 3.44B, up 6.71% year-over-year. In the year 2023, Ipsen had annual revenue of 3.31B with 4.75% growth.
Revenue (ttm)
3.44B EUR
Revenue Growth
+6.71%
P/S Ratio
n/a
Revenue / Employee
645.09K EUR
Employees
5,325
Market Cap
9.27B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.31B | 150.00M | 4.75% |
| Dec 31, 2022 | 3.16B | 407.80M | 14.84% |
| Dec 31, 2021 | 2.75B | 62.40M | 2.32% |
| Dec 31, 2020 | 2.69B | -6.60M | -0.25% |
| Dec 31, 2019 | 2.69B | 344.40M | 14.67% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sandoz Group AG | 10.11B |
| Telix Pharmaceuticals Limited | 430.80M |
| Elekta AB (publ) | 1.66B |
| Ryman Healthcare Limited | 458.44M |
| Verano Holdings Corp. | 897.57M |
| Vireo Growth Inc. | 98.53M |
| Medexus Pharmaceuticals Inc. | 104.76M |
Ipsen News
- 5 weeks ago - Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions - Seeking Alpha
- 2 months ago - Ipsen S.A. reports Q3 results; raises FY24 guidance - Seeking Alpha
- 3 months ago - Eton Pharmaceuticals to buy Increlex product from Ipsen - Seeking Alpha
- 3 months ago - Ipsen's Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease - Benzinga
- 3 months ago - Ipsen's Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade - Benzinga
- 3 months ago - Employee of French drugmaker Ipsen to plead guilty to US insider trading - Reuters
- 5 months ago - Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024) - GlobeNewsWire
- 7 months ago - Annual General Meeting of Ipsen S.A. held on 28 May 2024 - GlobeNewsWire